Telix Pharmaceuticals is trading 4.35% down at A$16.06 as investors reassess dilution from its proposed US$1.65 billion acquisition of ITM Isotope Technologies Munich.
- The transaction would issue approximately 105.8 million new Telix shares, leaving ITM shareholders with about 23.7% of the enlarged company, while Telix assumes additional debt.
- Reuters reported shares slipped after the announcement; the biotech sector is higher, making the decline company-specific.
- Trading remains volatile after the sharp 11.71% fall to A$15.76 on September 21 and subsequent rebound.